While intratumoral injection of TLR9 agonists (such as MGN1703 and IMO-2125) has shown preliminary clinical efficacy in treating superficial tumors, repeated administration remains clinically challenging, particularly for deep-seated or metastatic tumors. This evidence concerns the gene TLR9 and metastatic neoplasm.